Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen
- 1 October 1996
- journal article
- Published by Wiley in Tissue Antigens
- Vol. 48 (4) , 242-254
- https://doi.org/10.1111/j.1399-0039.1996.tb02642.x
Abstract
Interaction of the CD80 (B7-1) and CD86 (B7-2) molecules on antigen presenting cells with the receptors CD28 and CTLA-4 on T cells generates signals important in the regulation of immune responses. Because this receptor system involves multiple receptor-ligand interactions, determining the function for individual receptors has been difficult. One approach is the use of antibodies and their derivatives with singular specificity as substitute ligands to explore the activities of these molecules. We have constructed recombinant mono- and bi-specific sFv molecules specific for the CD28 receptor that are capable of binding and generating costimulatory signals to activate T cells. We demonstrate that these soluble molecules are capable of higher levels of costimulation than soluble CD80Ig at equivalent concentrations. We also constructed artificial adhesion receptors on the cell surface using two different CD28-specific sFvIgs fused to the CD80 cytoplasmic and transmembrane domains. In this report, we compared costimulation by a soluble bispecific (alpha CD28-alpha L6) single chain sFvIg fusion protein to that generated by L6 antigen positive (L6+) H3347 tumor cells transduced with cell surface expressed forms of alpha CD28 sFv's. We show that the bispecific protein can target potent CD28 costimulatory activity to L6+ tumor cells in vitro. We also show that transfection of the cell surface forms of the two different CD28 sFvIgs into H3347 tumor cells allows them to generate significant costimulatory signals to activated T cells. Finally, we demonstrate that tumor cell presentation of either the soluble bispecific or transduced cell surface sFv generate similar costimulatory effects resulting in T cell activation.Keywords
This publication has 50 references indexed in Scilit:
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragmentsTissue Antigens, 1996
- A genetically engineered single-chain FVTNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factorMolecular Immunology, 1995
- The X-ray structure of an anti-tumour antibody in complex with antigenNature Structural & Molecular Biology, 1995
- Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity, 1994
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.The Journal of Experimental Medicine, 1994
- Molecular Regulation of the IL‐2 Gene: Rheostatic Control of the Immune SystemImmunological Reviews, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Effect of gamma rays at the dihydrofolate reductase locus: Deletions and inversionsSomatic Cell and Molecular Genetics, 1986